Cargando…

XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA

Base excision repair (BER) removes damaged bases by generating single‐strand breaks (SSBs), gap‐filling by DNA polymerase β (POLβ), and resealing SSBs. A base‐damaging agent, methyl methanesulfonate (MMS) is widely used to study BER. BER increases cellular tolerance to MMS, anti‐cancer base‐damaging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirota, Kouji, Ooka, Masato, Shimizu, Naoto, Yamada, Kousei, Tsuda, Masataka, Ibrahim, Mahmoud Abdelghany, Yamada, Shintaro, Sasanuma, Hiroyuki, Masutani, Mitsuko, Takeda, Shunichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310723/ https://www.ncbi.nlm.nih.gov/pubmed/35194903 http://dx.doi.org/10.1111/gtc.12929

Ejemplares similares

ADP-ribosyltransferases Parp1 and Parp7 safeguard pluripotency of ES cells
por: Roper, Stephen J., et al.
Publicado: (2014)

Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib
por: Gravells, Polly, et al.
Publicado: (2018)

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
por: Gilabert, Marine, et al.
Publicado: (2014)

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
por: Miyasaka, Aki, et al.
Publicado: (2014)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
por: Qin, Changjiang, et al.
Publicado: (2022)

XRCC1 prevents toxic PARP1 trapping during DNA base excision repair
por: Demin, Annie A., et al.
Publicado: (2021)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
por: Agarwal, Ashok, et al.
Publicado: (2009)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
por: Ström, Cecilia E., et al.
Publicado: (2011)

PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions
por: Catara, Giuliana, et al.
Publicado: (2017)

New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage
por: Gu, Zongying, et al.
Publicado: (2019)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
por: De Soto, Joseph A., et al.
Publicado: (2006)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
por: Zhang, Zhimin, et al.
Publicado: (2020)

Damage response of XRCC1 at sites of DNA single strand breaks is regulated by phosphorylation and ubiquitylation after degradation of poly(ADP-ribose)
por: Wei, Leizhen, et al.
Publicado: (2013)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Stability of centrosome numbers in poly(ADP-ribose) polymerase-1- and poly(ADP-ribose) glycohydrolase-deficient mouse ES cells
por: Ogino, Hideki, et al.
Publicado: (2004)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites
por: Altmeyer, Matthias, et al.
Publicado: (2009)

Poly(ADP-Ribose) Polymerase 1 (PARP-1) Regulates Ribosomal Biogenesis in Drosophila Nucleoli
por: Boamah, Ernest K., et al.
Publicado: (2012)

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery
por: Noël, Georges, et al.
Publicado: (2003)

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
por: Fernández-Marcelo, Tamara, et al.
Publicado: (2014)

PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses
por: Song, Junqi, et al.
Publicado: (2015)

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
por: Perez-Lopez, Raquel, et al.
Publicado: (2017)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer
por: Desnoyers, A., et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability
por: Dhoonmoon, Ashna, et al.
Publicado: (2023)

Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice
por: Piskunova, Tatiana S., et al.
Publicado: (2008)

Poly(ADP‐ribose)‐mediated interplay of XPA and PARP1 leads to reciprocal regulation of protein function
por: Fischer, Jan M. F., et al.
Publicado: (2014)

Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
por: Sargazi, Saman, et al.
Publicado: (2021)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation
por: Iwata, Hiroshi, et al.
Publicado: (2016)

PARPs and ADP-ribosylation: 60 years on
por: Kraus, W. Lee
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qfvb9rs2dfu62offp2ohhp5fka